Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. In the U.S., Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and the fixed-dose combination Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% has received marketing authorization in the EU. Aerie has development operations in Europe and Japan, as well as a global manufacturing facility in Ireland, and is expanding its pipeline with clinical stage programs in dry eye and retina, and discovery programs based on its proprietary library of small-molecule multi-kinase inhibitors.
Line 1 Rocklatan®
Line 2 Rhopressa®